Cytokinetics, Incorporated Cytokinetics, Incorporated

Cytokinetics, Incorporated

CYTK

Rankning i aktier #2308
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Aktiekurs
$62.08
Marknadsvärde
$8.63B
Förändring (1 dag)
0.21%
Förändring (1 år)
6.23%
Land
US
Handel Cytokinetics, Incorporated (CYTK)

Kategori

Healthcare
Utdelningshistorik för Cytokinetics, Incorporated (CYTK)
Cytokinetics, Incorporated (aktiens symbol: CYTK) har gjort totalt 0 utdelningsbetalningar.
Summan av alla utdelningar (justerat för aktiesplitar) är: 0.00
Utdelningsavkastning (TTM): 0
Utdelningsbetalningar för Cytokinetics, Incorporated (CYTK) från 2026 till 2026
Årliga utdelningsbetalningar
År Utdelning (justerat för aktiesplitar) Ändra
Inte tillräckligt med data för de angivna datumen.
Lista över alla utdelningsbetalningar
År Utdelning Ändra
Inte tillräckligt med data för de angivna datumen.
Utdelningar för liknande företag eller konkurrenter
Företag Antal utdelningsbetalningar Land
0.00%
US
0.00%
US
64.00%
AU
0.00%
CH
0.00%
NL